Who Paid My Doc
Barry Reiner
Pediatric Endocrinology Baltimore, MD Medical Doctor
NPI 1386738938 CMS profile 289088
1001 Pine Heights Ave, Suite 202, Baltimore, MD 21229
General payments
$14,884
Research payments
$652,058
Ownership & investment interest
$0
Research they led as principal investigator
$1,442,872
Through program year 2025, Barry Reiner of Baltimore, MD is reported in the CMS Open Payments database as having received $14,884 across 324 general payments and $652,058 in research payments paid to them. Separately, studies naming them as principal investigator received $1,442,872 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,741 | 66 | |
| 2024 | General | $996 | 41 | |
| 2024 | Research | $81,696 | 12 | |
| 2023 | General | $1,181 | 40 | |
| 2023 | Research | $251,854 | 21 | |
| 2022 | General | $1,074 | 54 | |
| 2021 | General | $740 | 34 | |
| 2021 | Research | $125,767 | 512 | |
| 2020 | General | $987 | 25 | |
| 2020 | Research | $140,367 | 541 | |
| 2019 | General | $6,165 | 64 | |
| 2019 | Research | $52,374 | 17 |
Beside peers
- Barry Reiner
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Barry Reiner were reported at $3,741. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Barry Reiner | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $6,165 | $196 | $68–$845 | $163 |
| 2020 | $987 | $124 | $37–$722 | $114 |
| 2021 | $740 | $134 | $35–$691 | $132 |
| 2022 | $1,074 | $177 | $47–$726 | $149 |
| 2023 | $1,181 | $236 | $75–$887 | $160 |
| 2024 | $996 | $259 | $91–$979 | $164 |
| 2025 | $3,741 | $293 | $106–$1,640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
37
Drug cost
$27,702
Branded share of claims
29.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Omnitrope Somatropin | Brand | 11 | $27,510 | |
| Levothyroxine Sodium | Generic | 26 | $191 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 8 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Sogroya |
|
$221 | — | — |
| FENSOLVI |
|
$186 | — | — |
| TZIELD |
|
$137 | — | — |
| LUPRON DEPOT |
|
$54 | — | — |
| STRENSIQ |
|
$28 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 8 in the dashboard with a free accountRecords
1,427 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Endocrinology in Maryland
Maya Lodish
Pediatric Endocrinology · Bethesda, MD
David Cooke
Pediatric Endocrinology · Baltimore, MD
Risa Wolf
Pediatric Endocrinology · Baltimore, MD
Mary Roberts
Pediatric Endocrinology · Bethesda, MD
Ryan Miller
Pediatric Endocrinology · Baltimore, MD
Robert Kritzler
Pediatric Endocrinology · Lutherville, MD
Related records
Pediatric Endocrinology in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.